INTRODUCTION {#S2}
============

The common late-onset form of Alzheimer disease (AD) has a strong genetic component,^[@R1]^ a portion of which is explained by *APOE* and several other genes identified by positional mapping, targeted gene analysis and genome-wide association studies (GWAS).^[@R2]--[@R4]^ Together, these loci account for less than one-half of the heritable component in AD susceptibility, of which 20%--25% is due to *APOE*.^[@R4],[@R5]^ Because many of the known AD loci cluster in biological pathways, including those involved in inflammation, lipid metabolism and processing, and intracellular trafficking of Aβ, there are likely more AD risk loci that are difficult to detect because of very weak effect size, allelic heterogeneity, or rare variants. To examine yet another hypothesis, namely, that associations for some loci may be obscured by confounding or interaction with other loci, we conducted a two-stage GWAS in *APOE* genotype subgroups using the large resources of the International Genomics of Alzheimer's Project (IGAP).

METHODS {#S3}
=======

Study Population {#S4}
----------------

Details of the stage 1 sample from the International Genomics of Alzheimer's Project (IGAP) Consortium including subject recruitment, genotyping, imputation, quality control, population substructure, and statistical methods for association analyses were previously described.^[@R4]^ In brief, phenotype and genotype data, including *APOE* genotypes, for a total of 53,711 subjects were assembled by IGAP from the Alzheimer's Disease Genetic Consortium (ADGC), the Cohorts for Heart and Ageing Research in Genomic Epidemiology (CHARGE) consortium, the European Alzheimer's Disease Initiative (EADI), and the Genetic and Environmental Risk in Alzheimer's Disease (GERAD) consortium. Characteristics of this sample are in [Supplementary Table S1](#SD2){ref-type="supplementary-material"}.

The stage 2 dataset included GWAS and *APOE* genotype data for 4,203 subjects of European ancestry from the ADC4, ADC5, ADC6, MTV, Pfizer, and TARCC datasets in the ADGC. These individuals were recruited under protocols approved by the appropriate Institutional Review Boards. Details of the individual datasets are provided in the [Supplementary Materials](#SD1){ref-type="supplementary-material"} and summarized in [Supplementary Table S1](#SD2){ref-type="supplementary-material"}.

Procedures {#S5}
----------

### QC, Imputation, and Population Substructure in Stage 2 Datasets {#S6}

Quality control of the clinical and genotype data in these cohorts was performed using procedures described elsewhere.^[@R4]^ SNP genotypes in each stage 2 dataset were imputed with IMPUTE2 using reference haplotypes from the March 2012 release of 1000 Genomes. We compared imputation results for selected variants in the stage 1 datasets using the March 2012 release of 1000 Genomes and prior imputation on the December 2010 release, and found no significant difference in the distribution of genotype probabilities between old and new imputations for the same samples among the original ADGC datasets. We used actual *APOE* genotypes when available because previously we observed that imputation in this region using the 1000 Genomes reference panel is unreliable.^[@R5]^ Population substructure was evaluated within each dataset by principal components (PC) analysis using EIGENSTRAT (<http://www.hsph.harvard.edu/alkes-price/software/>) and a subset of 21,109 SNPs common to all genotyping platforms.

Statistical Analysis {#S7}
--------------------

### Genome-wide Association Study {#S8}

Within each stage 1 dataset, genome-wide association analyses were conducted separately in subgroups of subjects with and without the *APOE* ε4 allele using a logistic generalized linear model (GLM) in case-control datasets and a logistic generalized estimating equation (GEE) in family-based datasets. The potential independent effect of the *APOE* ε2 allele was not examined because of the paucity of carriers of this allele, thus rendering very small cell sizes particularly among AD cases and in smaller datasets. Cox-proportional hazards models were used to evaluate association with incident AD in three CHARGE cohorts. A quantitative estimate between 0 and 2 for the dose of the reference allele for a SNP was used to incorporate the uncertainty of the imputation estimates. Interaction between a SNP and *APOE* genotype was evaluated in the *APOE* genotype subgroups combined within each dataset using regression models including age, sex, the first three PCs, and terms for the SNP, *APOE* ε4 status, and interaction between the SNP and *APOE* ε4 status. Results for each model across datasets were combined by meta-analysis using the inverse variance method implemented in the software package METAL (<http://www.sph.umich.edu/csg/abecasis/Metal/>). Effect sizes were weighted by their inverse variance and a combined estimate was calculated by summing the weighted estimates and dividing by the summed weights. SNPs with a minor allele frequency \>5% that were available in at least 50% of the datasets were included in the meta-analysis. The meta-analysis *P-*value for association was estimated by the summarized test statistic, after applying genomic control within each individual study.

### Follow-up Analysis in Stage 2 Datasets {#S9}

SNPs attaining a P-value \<10^−4^ in the stage 1 GWAS were evaluated in each of the stage 2 GWAS datasets, containing a total of 1,786 *APOE* ε4+ and 2,417 *APOE* ε4− subjects ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}), using the same approach described above.

Gene Expression Analysis {#S10}
------------------------

The effect of top-ranked SNPs on gene expression was evaluated using an open access database of control brain microarray data (BRAINEAC) made publically available by the UK Human Brain Expression Consortium (<http://caprica.genetics.kcl.ac.uk/BRAINEAC>). This dataset contains information generated by analysis of tissue samples obtained from 12 different central nervous system regions in 134 individuals. Details of the expression quantitative trait locus (eQTL) analysis are reported elsewhere.^[@R6]^ In this study, the experiment-wise significance threshold for association of a genetic marker with expression was determined to be 1.6x10^−7^ at the gene level and 1.8x10^−6^ for individual exons. Potential for functionality of the top-ranked SNPs was assessed using the Regulome database (<http://www.regulomedb.org>).

RESULTS {#S11}
=======

We conducted a genome-wide association study for AD using datasets stratified by *APOE* genotype assembled by IGAP which were from the ADGC, CHARGE consortium, EADI, and GERAD consortium. Meta-analyses were performed separately in *APOE* ε4+ (10,246 cases and 11,924 controls) and *APOE* ε4− (7,231 cases and 19,603 controls) subgroups, as well as the total sample using a model including a term for the interaction of the SNP with the *APOE* ε4 status. There was limited genomic inflation in the GWAS results in the *APOE* ε4+ (λ=1.05) and *APOE* ε4− (λ=1.06) groups, but not in the total sample (λ=0.98) testing the ε4 \* SNP interaction ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Genome-wide significant (GWS) association (P\<5x10^−8^) for AD was found in five distinct regions (*CR1, BIN1, CLU, PICALM* and *APOE*) in the *APOE* ε4+ subgroup ([Supplementary Figure S2A](#SD1){ref-type="supplementary-material"}, [Supplementary Table S2](#SD2){ref-type="supplementary-material"}) and four distinct regions (*BIN1*, *HBEGF*, *MS4A6A/MS4A4A*, *SLC24A4*, and *APOE*) in the *APOE* ε4− subgroup ([Supplementary Figure S2B](#SD1){ref-type="supplementary-material"}, [Supplementary Table S2](#SD2){ref-type="supplementary-material"}). No significant SNP\**APOE* interactions were found in the total group ([Supplementary Figure S2C](#SD1){ref-type="supplementary-material"}). Suggestive association (P\<10^−6^) was observed with SNPs in five novel loci in the *APOE* ε4− subgroup (*SOX14/CLDN18*, *ACSL6*, *FAM20C*, *MAPT* region, and *CDR2L*; [Supplementary Figure S2B](#SD1){ref-type="supplementary-material"}, [Supplementary Table S3](#SD2){ref-type="supplementary-material"}) and with 21 *TMEM106B* SNPs (top result: rs1595014, P=1.6x10^−7^) ([Supplementary Figure S2C](#SD1){ref-type="supplementary-material"}, [Supplementary Table S3](#SD2){ref-type="supplementary-material"}).

Approximately 1,130 SNPs from 38 regions (including seven previously established AD loci) were tested in Stage 2 ([Supplementary Table S3](#SD2){ref-type="supplementary-material"}). Follow-up analyses of the novel loci confirmed association with SNPs in *CDC42SE2-ACSL6, KANSL1/LRRC37A*, and *CDR2L* in the stage 2 sample ([Table 1](#T1){ref-type="table"}, [Supplementary Table S2](#SD2){ref-type="supplementary-material"}), but only SNPs near *MAPT* and between *KANSL1* and *LRRC37A* ([Figure 1A](#F1){ref-type="fig"}) were genome-wide significant after combining results from the stage 1 and stage 2 samples (best SNP: rs2732703, meta-analysis: P=5.8x10^−9^). The association was consistent in nearly all datasets which contained rs2732703 information ([Figure 1B](#F1){ref-type="fig"}). To verify the reliability of the association with rs2732703, an imputed SNP, we compared rs2732703 allele dosages obtained directly by genotyping using a Taqman assay with those derived from imputation among 1,010 subjects from the ACT, ADC4, ADC5 and ADC6 datasets. The correlation of these values, 0.813 in the entire sample and 0.834 among *APOE* ε4− subjects, as well as a genotype misclassification rate of only 3.5% among subjects with imputed probability scores \> 0.8 for a particular genotype, suggest that our association findings were not influenced substantially by imputation quality.

Further examination of this region in the total sample revealed an association peak spanning more than 1.25 Mb that contains 15 genes ([Figure 1A](#F1){ref-type="fig"}). Within this region, 17 SNPs were GWS, have MAFs ranging from 0.13 to 0.17, and are located in a 10.2 kb segment upstream of both *KANSL1* and *LRRC37A* ([Supplementary Table S4](#SD2){ref-type="supplementary-material"}). Nominally significant association was observed with only one of these SNPs among ε4+ subjects (rs2732703, P=0.02) ([Supplementary Table S3](#SD2){ref-type="supplementary-material"}). Although the odds ratios (OR) for effect of the effect of minor allele on AD risk were substantially lower for all of the GWS SNPs in the ε4− group (0.54\< OR \<0.86) than in the ε4+ group (0.76\< β \<1.04), there was no evidence of interaction with *APOE* genotype ([Supplementary Table S3](#SD2){ref-type="supplementary-material"}). The minor alleles of these SNPs reduced AD risk by 20%--37% in the ε4− group. The 350 kb gap in the broad association signal is punctuated at one end by a "cliff" adjacent to the *MAPT-KANSL1-LRRC37A* association peak ([Figure 1](#F1){ref-type="fig"}). This gap is populated by relatively few SNPs and contains several copy number variation (CNV) polymorphisms.^[@R7],[@R8]^ To explore the possibility that the association observed in the present analysis is explained by previously identified haplotypes H1/H2 in the *MAPT* region,^[@R8]^ we evaluated six models in the entire dataset conditioning on rs8070723 (an H1/H2 tagging SNP), rs2732703, or rs199533. Rs2732703 remained significant in models conditioning on rs8070723 (P=0.013) or rs199533 (P=0.0020), and rs8070723 was marginally significant in the model conditioning on rs199533 (P=0.043) ([Supplementary Table S5](#SD2){ref-type="supplementary-material"}, [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). These results suggest that *KANSL1/LRRC37A* is the only AD risk locus in this region.

We also examined the effect of *APOE* ε4 status on previously established AD loci ([Supplementary Table S2](#SD2){ref-type="supplementary-material"}). Four of these loci attained genome-wide significance in at least one of the *APOE* subgroups ([Table 2](#T2){ref-type="table"}), and the association signal in the *MS4A* cluster region was evident primarily in the *APOE* ε4− subgroup ([Supplementary Figure S4](#SD1){ref-type="supplementary-material"}). The association of AD with *CR1, BIN1,* and *CLU* was supported in both *APOE* subgroups.

Next, we interrogated the BRAINEAC database to determine whether any of the 17 GWS SNPs located between *KANSL1* and *LRRC37A* are cis-eQTLs. Data were available for only one of these SNPs (rs113986870) which is in high LD with and 2,461 base pairs away from rs2732703 (r^2^ and D′\>0.9). Ten exon probes from four genes (*KANSL1, LRRC37A4P, MAPT,* and *C17orf69*) were significantly associated with rs113986870 when averaged across all brain regions ([Table 3](#T3){ref-type="table"}). Rs113986870 was significantly associated with gene-level expression ([Figure 2A](#F2){ref-type="fig"}) as well as with exon-level expression ([Figure 2B](#F2){ref-type="fig"}) in hippocampus, temporal cortex, and cerebellum. In these brain regions, rs113986870 was significantly associated with *KANSL1* probes 3762011, 3762012 and 3762013 that measure expression of the first translated exon. Additionally, we observed that expression of probe 3760518 ([Supplementary Figure S5A](#SD1){ref-type="supplementary-material"}) present in all three transcripts (NM_001193466, NM_015443, and NM_001193465) and 3760219 in transcript variant 2 (NM_015443) was significantly associated with rs113986870 ([Supplementary Figure S5B](#SD1){ref-type="supplementary-material"}), while expression of probe 3760217 in transcript variant 1 ((NM_001193466) was not significant ([Supplementary Figure S5C](#SD1){ref-type="supplementary-material"}), indicating that alternative splicing may be a crucial mechanism for regulating *KANSL1* expression. Rs113986870 was also strongly associated with *MAPT* transcription ([Supplementary Figure S6A](#SD1){ref-type="supplementary-material"}) and in particular with probe 3723712 that targets transcription of alternatively spliced exon 3 in frontal cortex (P≤9.2x10^−6^) and temporal cortex (P≤2.6x10^−6^) ([Supplementary Figure S6B](#SD1){ref-type="supplementary-material"}). The rs113986870 minor allele (*A*), which is associated with reduced risk of AD ([Supplementary Table S4](#SD2){ref-type="supplementary-material"}), increased expression of the target exons in *KANSL1* and *MAPT* ([Figure 2](#F2){ref-type="fig"}, [Supplementary Figure S6](#SD1){ref-type="supplementary-material"}, [Supplementary Figure S7](#SD1){ref-type="supplementary-material"}). The association with *LRRC37A4P* exon probe 3759898 was significant in all three AD-related brain regions (P≤3.6x10^−9^). The association of rs113986870 with exon probe 3723594 for *C17orf69* was significant in hippocampus only (P=1.6x10^−7^). Five of the GWS SNPs including rs2732703 and rs113986870 are located within a transcription factor binding site or a DNase sensitivity peak and two of these five SNPs, including rs2668626 which is only 47 bp from rs2732703, have also been identified within an eQTL ([Supplementary Table S4](#SD2){ref-type="supplementary-material"}).

DISCUSSION {#S12}
==========

This study was undertaken to identify loci whose effect on AD risk may be obscured by confounding or interaction with *APOE* genotype. Our *APOE*-stratified GWAS is the first to show GWS association for AD with SNPs in the chromosome 17q21.31 region including *MAPT, KANSL1* and *LRRC37A*. Among the genes expected to emerge from GWAS but never seen before is *MAPT* which encodes the microtubule-associated protein tau (*MAPT*) found in AD neurofibrillary tangles. The association peak is located between *KANSL1* and *LRRC37A*, approximately 200 kb downstream of *MAPT*, in a subset of subjects that do not possess the *APOE* ε4 allele. Although the association signal includes *MAPT*, conditional analysis suggests that the causal variant(s) are more likely located in a DNA segment between the 5′ end of *KANSL1* and 5′ end of *LRRC37A* and not within *MAPT* or another gene distal to *LRRC37A*.

The nature of the AD-related functional variant could not be discerned from our genetic association findings. None of the GWS SNPs are within 42.1 kb of the *KANSL1* start site or 16.8 kb of the *LRRC37A* start site, suggesting that the functional variant is not within the promoter region of either gene. *KANSL1* is a widely expressed gene encoding a member of the nonspecific lethal (NSL) complex. The KANSL1 protein is an evolutionarily conserved regulator of the chromatin modifier KAT8, which influences gene expression through histone H4 lysine 16 (H4K16) acetylation.^[@R9]^ Notably, mutations in *KANSL1* cause the 17q21.31 microdeletion syndrome which is associated with a wide range of abnormalities including intellectual disability and developmental delay, and is therefore thought to be involved in neuronal development.^[@R10],[@R11]^ *LRRC37A* encodes a member of the leucine-rich repeat containing 37 family. Leucine-rich repeats (LRRs) are protein-ligand interaction motifs found in a large number of proteins with different structure, localization, and function.^[@R12]^ LRR motifs are important for intermolecular or intercellular interactions with exogenous factors in the immune system and/or with different cell types in the developing nervous system.^[@R12]^

However, expression analysis of exon array data in control brain tissue revealed that rs113986870, which is in high LD with the top-ranked SNP (rs2732703) in the GWAS, is an eQTL for expression of the first translated exon in *KANSL1* and the alternatively spliced exon 3 in *MAPT*. Previous studies suggest that splicing of *MAPT* may be a crucial regulatory mechanism in the brain and tauopathies in particular,^[@R13]^ and that increased expression of exon 3 protects against neurodegeneration.^[@R14]^ Although rs113986870 is apparently not an eQTL for its adjacent gene *LRRC37A*, it was significantly associated with a closely related gene, *LRRC37A4P*, in all three AD-related brain regions. These results suggest that rs113986870 may have a potential function as a cis-acting regulatory element for multiple genes in this region. Another confounding feature of this region are copy number variations that in part overlap with the 5′ end of *KANSL1* and possibly influence expression.^[@R7],[@R8]^ Thus, it is possible that the exon probes targeting the first translated in *KANSL1* may be tagging this duplication. In addition, interrogation of a database curating information about DNA features and regulatory regions revealed that five of the GWS SNPs, including rs2732703 and rs113986870, may have strong regulatory potential.

The association peak for AD on chromosome 17q21.31 is located in a well-recognized and perplexing genomic region containing a 900 kb inversion.^[@R8]^ Previous GWAS identified associations of variants within and at the edges of this inversion with Parkinson disease (PD)^[@R15]^ and progressive supranuclear palsy (PSP),^[@R16]^ but the most significant associations were not with SNPs between *KANSL1* and *LRRC37A* ([Supplementary Table S6](#SD2){ref-type="supplementary-material"}). Multiple studies have identified more than 40 *MAPT* deletions, missense mutations, and splice site mutations that cause frontotemporal dementia (FTD).^[@R17]^ Although AD is only nominally associated with common variants in *MAPT*, previously we observed association of a rare *MAPT* variant (A152T) with increased risk for FTD and AD in a large sample,^[@R18]^ a finding which was supported by a subsequent smaller study.^[@R19]^ Ikram et al identified a GWS association peak with a *KANSL1* SNP approximately 166 kb away from our most significant AD SNP (rs2732703) for a continuous measure of intracranial volume in a sample of nearly 10,000 community-dwelling elders ([Supplementary Table S6](#SD2){ref-type="supplementary-material"}).^[@R20]^ These two SNPs are moderately correlated (r^2^=0.71) which indicates that they may tag the same functional variant.

Other studies have focused on two divergent extended *MAPT* haplotypes, H1 and H2, which are in near complete LD with status of the inversion and contain independently derived partial duplications of *KANSL1*.^[@R8],[@R16]^ The common H1 haplotype is associated with increased risk of FTD,^[@R21]^ PD,^[@R22]^ PSP,^[@R23]^ and corticobasal degeneration (CBD),^[@R23]^ while H2 is linked to recurrent deletion events associated with the 17q21.31 microdeletion syndrome.^[@R10]^ Among these non-AD forms of dementia, it is possible for FTD to masquerade clinically as AD and thereby cases of FTD could be present in our study group; however, any inadvertent inclusion of FTD cases is expected to be very small since the minimum age of dementia onset in our study group was 60 years and onset of dementia from FTD after age 69 years is relatively rare compared to AD that in most cases occurs after age 69.^[@R24]^ Furthermore, a recent review of almost 5000 autopsy brains from a subset of cases in the ADGC cohort failed to identify any case of FTD.^[@R25]^ Myers et al. reported association of AD with H1 and with common *MAPT* SNPs,^[@R26]^ but this association is controversial^[@R27]^ and did not reach genomewide significance in our study or previous GWAS. Another recent study showed that carriers of at least one H2 allele had a 5.4-fold increased risk of worsening hallucinations, but this result was marginally significant.^[@R28]^ Previously, we observed in a subset of the sample studied here that the H2-haplotype tagging rs8070723-G allele was associated with reduced risk of AD.^[@R29]^ However, this variant is no longer associated after conditioning on rs2732703 ([Supplementary Table S5](#SD2){ref-type="supplementary-material"}). In carriers of H2, the ancestral haplotype in both humans and chimpanzees,^[@R30]^ increased expression of exon 3 in *MAPT* has been associated with an eQTL located approximately 1,500 bp from rs113986870 which decreases aggregation of microtubules.^[@R31],[@R32]^ These observations are consistent with our results showing that the rs113986870 minor allele is protective for AD and associated with elevated exon3 expression.

There is a large body of experimental evidence linking tau protein to AD pathogenesis,^[@R33]^ and some studies show evidence of association of AD with common *MAPT* SNPs.^[@R29],[@R34]^ However, analysis of the *MAPT* coding sequence did not reveal disease-causing variants for early-onset AD ^[@R35]^ and other studies examining association of *MAPT* SNPs with late-onset AD were negative.^[@R27],[@R36]^ Recently, Allen et al. reported that the rs8070723-G allele was associated with reduced *MAPT* expression in the cerebellum and temporal cortex of AD subjects.^[@R29]^ Robust genetic associations have also been identified for AD with several genes in cytoskeletal and axonal transport pathways including tau or leading to neurofibrillary tangles, most notably *BIN1, EPHA1, RIN3, CASS4,* and *FERMT2*.^[@R4]^

Based on the observation that overexpression of human ApoE4 in transgenic mouse neurons results in hyperphosphorylation of tau,^[@R37]^ it is possible that associations with AD-related loci in the chromosome 17q21.31 region are obscured by the much stronger effect of *APOE* ε4 on *MAPT* expression or function.^[@R38]^ This idea is consistent with lack of GWS association with 17q21.31 SNPs in the same dataset without stratification by *APOE* genotype,^[@R4]^ and no evidence for interaction between *APOE* and any SNPs in the *MAPT-KANSL1-LRRC37A* region in the current study. Another possible explanation for the significant association of 17q21.31 SNPs with AD only among subjects lacking *APOE* ε4 is genetic heterogeneity suggesting that variation at the chromosome 17q21.31 locus is associated with a distinct etiological subtype of AD where tau is the primary disease activator.^[@R39]^ Finally, the diagnosis of AD for most subjects in this dataset was established clinically suggesting the possibility of misdiagnosis or AD accompanied by other processes associated with other dementing illnesses. Further studies are needed to determine whether this subtype can be distinguished clinically or neuropathologically.

Our study also showed that the previously established association with the *MS4A* gene cluster is derived almost completely from subjects lacking *APOE* ε4, suggesting the contribution of the *MS4A* locus to AD may be mechanistically different than AD-related processes that are associated with *APOE* ε4. Members of the MS4A gene family encode membrane proteins, some of which have known roles in immune cell function,^[@R40]^ however, little is known about the function of *MS4A6A, MS4A4A* or *MS4A6E* in humans. Karch et al. showed that expression of *MS4A6A* was upregulated in AD brains of AD patients compared to brains of controls, and significantly correlated with AD status, AIF1 expression (a marker for microglia which is the immune cell of the brain), cognitive dementia rating score, and extent of AD neuropathologic change.^[@R41]^

The observed statistical interaction of genotypes for *TMEM106B* with *APOE* on AD risk in the stage 1 GWAS is noteworthy (rs1595014, P=1.6x10^−7^) even though it is not supported by results in the comparatively small stage 2 sample. TMEM106B is a glycoprotein predominantly localized at the lysosomal membrane where it might interact with intracellular progranulin (GRN).^[@R42],[@R43]^ *TMEM106B* variants, particularly the p. T185S (rs3173615) mutation, are risk factors for FTD, especially among persons carrying a *GRN* mutation.^[@R44]^ *TMEM106B* variants are also associated with development of cognitive impairment in amyotrophic lateral sclerosis^[@R45]^ and implicated in the pathologic presentation of AD.^[@R46]^ Cruchaga et al observed association of the *TMEM106B* SNP rs1990622 risk allele with younger onset of the FTLD subtype with TAR DNA-binding protein inclusions (FTLD-TDP),^[@R47]^ a pattern reminiscent of the association of *APOE* ε4 with increased risk and younger onset of AD. The biological underpinning of the interaction of *TMEM106B* with *APOE* affecting AD risk is unclear.

Our top findings, including those that are genome-wide significant, should be confirmed in independent samples. Functional studies will be needed to understand the relationship between *APOE* and the causative variant(s) in 17q21.31 once they are identified, as well as with other loci showing much stronger association with AD in particular *APOE* genotype strata (e.g., *MS4A6A/MS4A4A/ MS4A6E*) or through interaction with *APOE* (e.g., *TMEM106B*). Our study provides a firm genetic connection of AD to several other pathologically distinct disorders in which dementia is a cardinal or common characteristic.
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======================
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![Association of AD with SNPs in chromosome 17q21.31 in the combined stage 1 and stage 2 samples. **(A)** Regional Manhattan plot in the *APOE* ε4+ (upper panel) and the *APOE* ε4− (lower panel) subgroups. SNPs with the lowest *P*-value are indicated with a purple diamond. Computed estimates of linkage disequilibrium (r^2^) of SNPs in this region with the most significant SNP are shown as red circles for r^2^ ≥ 0.8, orange circles for 0.6 ≤ r^2^ \< 0.8, green circles for 0.4 ≤ r^2^ \< 0.6, light blue circles for 0.2 ≤ r^2^ \< 0.4, and blue circles for r^2^ \< 0.2. Unannotated SNPs are shown as grey circles. **(B)** Forest plot of association results for rs2732703 in the Stage 1, Stage 2 and total samples among *APOE* ε4− subjects.](nihms654371f1){#F1}

![Genotype specific effect of the eQTL rs113986870 on expression of *KANSL1*. **(A)** Gene-level expression of *KANSL1* transcript t3760137. Transcript-level expression represents the average across all *KANSL1* exon probe sets. **(B)** Expression of exon probe 3760212. Probes 3760211, 3760212, and 3760213 measure expression of the first translated exon, are present in all three transcript variants, and were significantly associated with the eQTL. Expression profiles for probes 3760211 and 3760213 showed similar to those for probe 3760212 ([Table 3](#T3){ref-type="table"}). The distance from 3760212 to rs113986870 is 85,431 base pairs. Log2 scale of expression (Y-axis) is shown for 10 regions of cognitively normal human brains (X-axis) ordered by mean expression level. Rs113986870 genotype counts: AA=0, AG=56, and GG=76. Rs113986870 allele frequencies are 0.21 (A) and 0.79 (G). **CRBL =** cerebellum, **FCTX** = frontal cortex, **HIPP** = hippocampus, **MEDU** = medulla (specifically inferior olivary nucleus), **OCTX** = occipital cortex (specifically primary visual cortex), **PUTM** = putamen, **SNIG** = substantia nigra (SNIG), **THAL** = thalamus, **TCTX** = temporal cortex), **WHMT** = intralobular white matter.](nihms654371f2){#F2}

###### 

Association results (P\<10^−6^) in novel AD loci among APOE ε4− subjects in the combined stage 1 and stage 2 samples.

  SNP          CH   Region or Closest Gene   MA   MAF    Stage 1             Stage 2      Stages 1 + 2                                    
  ------------ ---- ------------------------ ---- ------ ------------------- ------------ ------------------- ------- ------------------- ------------
  rs16847609   3    SOX14/CLDN18             A    0.09   1.21 (1.12--1.29)   2.3x10^−7^   1.09 (0.87--1.37)   0.47    1.19 (1.11--1.28)   5.3x10^−7^
  rs382216     5    CDC42SE2-ACSL6           T    0.36   0.88 (0.83--0.93)   6.5x10^−6^   0.78 (0.67--0.91)   0.002   0.87 (0.82--0.92)   2.0x10^−7^
  rs11168036   5    PFDN1/HBEGF              T    0.50   1.14 (1.09--1.19)   9.3x10^−9^   0.97 (0.85--1.11)   0.64    1.12 (1.07--1.17)   3.2x10^−7^
  rs2732703    17   KANSL1/LRRC37A           G    0.13   0.73 (0.65--0.83)   6.4x10^−7^   0.71 (0.58--0.88)   0.001   0.73 (0.65--0.81)   5.8x10^−9^
  rs71380849   17   CDR2L                    A    0.06   1.45 (1.24--1.70)   3.8x10^−6^   1.59 (1.01--2.50)   0.04    1.47 (1.26--1.71)   9.1x10^−7^

###### 

Results (P\<10^−6^) in previously known AD loci showing different pattern of association among APOE ε4+ and ε4− subjects in the combined datasets.

  SNP         CH   Region or Closest Gene   MA   MAF    *APOE* ε*4(+)*        *APOE* ε*4(−)*                         
  ----------- ---- ------------------------ ---- ------ --------------------- ---------------- --------------------- -------------
  rs679515    1    CR1                      T    0.21   1.22 (1.14 --1.30)    3.6x10^−9^       1.13 (1.07 -- 1.19)   1.6x10^−5^
  rs4663105   2    BIN1                     C    0.43   1.19 (1.12 -- 1.25)   2.5x10^−9^       1.19 (1.13 -- 1.24)   1.8x10^−12^
  rs9331896   8    CLU                      C    0.38   0.84 (0.80 -- 0.89)   2.8x10^−9^       0.90 (0.86 -- 0.94)   9.6x10^−6^
  rs1582763   11   MS4 region               A    0.37   0.92 (0.87 -- 0.97)   0.003            0.87 (0.83 -- 0.91)   2.2x10^−9^

CH = chromosome; MA = minor allele; MAF = minor allele frequency.

###### 

Exon probes covering the region between 43.5 and 45.0 Mb on chromosome 17 that reveal significant rs113986870 allelic expression differences averaged over of 10 brain areas

  Gene        ExprID    Start      End        AVGALL        FCTX          HIPP          TCTX
  ----------- --------- ---------- ---------- ------------- ------------- ------------- -------------
  LRRC37A4P   3759896   43583231   43583802   1.4x10^−15^   6.4x10^−4^    4.0x10^−6^    2.4x10^−5^
  LRRC37A4P   3759898   43584264   43584884   1.7x10^−20^   8.0x10^−11^   5.3x10^−10^   3.6x10^−9^
  C17orf69    3723594   43716765   43716853   3.3x10^−13^   2.0x10^−5^    1.6x10^−7^    8.3x10^−5^
  C17orf69    3723604   43723359   43723556   4.9x10^−10^   0.004         9.8x10^−4^    1.3x10^−5^
  MAPT        3723712   44051752   44051833   3.6x10^−14^   9.2x10^−6^    7.6x10^−4^    2.6x10^−6^
  KANSL1      3760158   44117069   44117161   9.8x10^−14^   2.8x10^−5^    0.008         6.2x10^−5^
  KANSL1      3760211   44247654   44247852   4.0x10^−23^   8.0x10^−13^   3.0x10^−17^   1.6x10^−15^
  KANSL1      3760212   44248224   44248977   1.4x10^−24^   2.6x10^−18^   7.8x10^−20^   2.5x10^−21^
  KANSL1      3760213   44249529   44249592   7.7x10^−16^   3.0x10^−11^   1.1x10^−13^   1.2x10^−11^
  KANSL1      3760219   44270189   44270252   4.3x10^−13^   1.3x10^−9^    1.3x10^−8^    1.3x10^−11^

Map position is based on 1000 Genomes database release GRCh37/hg19 assembly, February 2009. Significance threshold after multiple testing determined as 0.05/292,000 exon probes = 1.7x10^−7^; ExprID: exon-specific probeset ID. AVEALL: average expression levels across 10 regions including cerebellum (CRBL), frontal cortex (FCTX), hippocampus (HIPP), medulla (specifically inferior olivary nucleus, MEDU), occipital cortex (specifically primary visual cortex, OCTX), putamen (PUTM), substantia nigra (SNIG), thalamus (THAL), temporal cortex (TCTX), and intralobular white matter (WHMT).
